## Ajay Mansukhlal Patel

103, Karuna Sagar Society, Umra, Near Umrigar School, Surat - 395007, Gujarat, India.

Date: 07 September 2023

To,

Tatva Chintan Pharma Chem Limited

Plot No. 502/17, GIDC Estate, Ankleshwar – 393 002,

District: Bharuch, Gujarat, India.

The General Manager, Corporate relationship

department, BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort, Mumbai-400001 Scrip Code: 543321 The Manager, Listing department, National Stock Exchange of

India Limited, Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex,

Bandra(E), Mumbai-400051 Scrip Symbol: TATVA

Subject: Filing of report under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended ("SEBI Takeover Regulations").

Dear Sir / Madam,

This is with reference to the intimation dated 05 September 2023 ("Intimation") filed with the BSE Limited and National Stock Exchange of India Limited (as defined hereinunder), pursuant to which I, Ajay Mansukhlal Patel, a member of Promoter/Promoter group of Tatva Chintan Pharma Chem Limited (the "Company") proposed to sell up to 7,190 equity shares of the Company having face value of ₹ 10 each ("Equity Shares"), (representing 0.031% of the total issued and paid up equity share capital of the Company) in accordance with the requirement of Rule 19(2)(b) and 19(A) of Securities Contracts (Regulation) Rules, 1957 and Regulation 38 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with para 3(7) of the SEBI Circular No. SEBI/HO/CFD/PoD2/P/CIR/2023/18 dated February 3, 2023 ("Circular") in connection with manner of achieving minimum public shareholding.

In this regard, I wish to inform you that I have sold 7,190 Equity Shares on 06 September 2023 representing 0.031% of the total issued and paid-up equity share capital of the Company.

In compliance with Regulation 29(2) of the SEBI Takeover Regulations, I am hereby notifying the information regarding sale of Equity Shares made by me on 06 September 2023. As required under Regulation 29(3) of SEBI Takeover Regulations, I am informing you about the said sale within 2 working days of such sale.

Enclosed is the report in the format as prescribed by the Securities and Exchange Board of India.

The above is for your information and records.

Yours sincerely,

Name: Ajay Mansukhlal Patel

## DISCLOSURES UNDER REGULATION 29(2) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011, AS AMENDED

1.	Name of the Target Company (TC)	Tatva	Chinta	n Pharma Chem	Limited (the
		"Comp	angulchl	ol Patel (the "Seller"	<i>y</i>
2.	Name(s) of the acquirer/ seller and Persons Acting in Concert (PAC) with the acquirer	Ajay Mansukhlal Patel (the "Seller")			
3.	Whether the acquirer/ seller belongs to Promoter/Promoter Group	Yes, the Seller is the member of Promoter/Promoter group of the Company.			
4.	Name(s) of the Stock Exchange(s) where the shares of TC are listed	BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")			
5.	Details of the acquisition/disposal as follows	Num		% w.r.t. total share/voting capital wherever applicable	% w.r.t. total dilluted share/voting capital of TC(*)
	e the acquisition/disposal under consideration,				
holdii	ng of:	40.0	7,190	17.131	17.131
a)	Shares carrying voting rights	40,0	Nil	Nil	Nil
b)	Shares in the nature of encumbrance (Pledge/Lien/ non- disposal undertaking/others)		INII	\$ 1000	
c)	Voting rights (VR) otherwise than by equity shares		Nil	Nil	Nil
d)	Warrants/ convertible securities/ any other instrument that entitles the acquirer/ seller to receive shares carrying voting rights in the		Nil	Nil	Nil
m . 1	TC (specify holding in each category)	40.0	07,190	17.131	17.131
Total	(a+b+c+d)	10,	07,170		
Detai a)	ils of <del>acquisition</del> /sale Shares carrying voting rights <del>acquired</del> /sold		7,190	0.031	0.031
b)	VRs acquired/sold otherwise than by shares		Nil	Nil	Ni
c)	Warrants/convertible securities/any other instrument that entitles the acquirer/ seller to receive shares carrying voting rights in the TC(specify holding in each category)		Nil	Nil	Ni
d)	acquired/sold  Shares encumbered/ invoked/ released by		Nil	Nil	Ni
	the acquirer/ seller		7,190	0.031	0.03
Tota	l (a+b+c+/-d)		7,150	1,1,1,1	
	r the acquisition/sale, holding of:	40	,00,000	17.100	17.10
a)	Shares carrying voting rights	10.	Nil		Ni
b)	Shares encumbered with the acquirer	-	Nil		Ni
d)	VRs otherwise than by shares  Warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition/ sale.		Nil		N
Tota	al (a+b+c+d)	40	,00,000	17.100	
6.	Mode of acquisition/sale (e.g. open market/off - market/ public issue/ rights issue/preferential allotment/inter-se transfer, etc.)	Open Market - Sale of equity shares of Tatva Chintan Pharma Chem Ltd ("Company") having face value of			

		(Listing Obligations and Disclosure Requirements) Regulations, 2015 read with para 3(7) of the SEBI Circular No. SEBI/HO/CFD/PoD2/P/CIR/2023/18 dated February 3, 2023 ("Circular") in connection with manner of achieving minimum public shareholding.
7.	Date of acquisition/sale of shares/ <del>VR or date of receipt of intimation of allotment of shares</del> , whichever is applicable	06 September 2023
8.	Equity share capital/ total voting capital of the TC before the said acquisition/sale	Number of Shares: 2,33,92,055 Amount (in ₹): 23,39,20,550 (Face value of ₹ 10 per equity share)
9.	Equity share capital/ total voting capital of the TC after the said acquisition/sale	Number of Shares: 2,33,92,055  Amount (in ₹): 23,39,20,550  (Face value of ₹ 10 per equity share)
10.	Total diluted share/ voting capital of the TC after the said acquisition/sale(*)	Number of Shares: 2,33,92,055  Amount (in ₹): 23,39,20,550  (Face value of ₹ 10 per equity share)

Yours sincerely,

Name: Ajay Mansukhlal Patel